Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). 


The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.

Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development Officer
Highly experienced clinical drug developer to oversee R&D functions and Companys Phase 3 development program
Trevi Therapeutics Raises $50 Million Series C Financing Led by New Enterprise Associates
Company continuing the development of Nalbuphine ER in chronic pruritus conditions
Trevi Therapeutics Names Michael Heffernan to its Board of Directors
Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine ER in chronic pruritus conditions